PIAGGIO & C SPA (OTCMKTS:PIAGF) had a decrease of 26.08% in short interest. PIAGF’s SI was 390,600 shares in February as released by FINRA. Its down 26.08% from 528,400 shares previously. With 1,200 avg volume, 326 days are for PIAGGIO & C SPA (OTCMKTS:PIAGF)’s short sellers to cover PIAGF’s short positions. It closed at $2.7057 lastly. It is down 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Analysts expect Knight Therapeutics Inc. (TSE:GUD) to report $0.04 EPS on March, 15.They anticipate $0.02 EPS change or 33.33% from last quarter’s $0.06 EPS. T_GUD’s profit would be $5.71M giving it 49.00 P/E if the $0.04 EPS is correct. After having $0.03 EPS previously, Knight Therapeutics Inc.’s analysts see 33.33% EPS growth. The stock increased 1.16% or $0.09 during the last trading session, reaching $7.84. About 68,501 shares traded. Knight Therapeutics Inc. (TSE:GUD) has 0.00% since February 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Among 2 analysts covering Knight Therapeutics (TSE:GUD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Knight Therapeutics had 11 analyst reports since May 12, 2016 according to SRatingsIntel. TD Securities maintained the shares of GUD in report on Friday, March 17 with “Buy” rating.
Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company has market cap of $1.12 billion. The company's commercialized products include Impavido, an alkyllysophospholipid analogue drug for the treatment of visceral and cutaneous Leishmaniasis; Movantik for the treatment of opioid induced constipation; AzaSite to treat bacterial conjunctivitis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Flat Tummy Tea, a herbal detox tea; and FOCUSfactor, a dietary supplement. It has a 62.72 P/E ratio. The Company’s products under development comprise Probuphine to treat opioid addiction; NeurAxon family to treat acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; Iluvien to treat diabetic macular edema; and Netildex to treat ocular inflammation.
Piaggio & C. SpA, together with its subsidiaries, develops, makes, and distributes two-wheeler and commercial motor vehicles. The company has market cap of $958.08 million. It offers two-wheelers, including scooters, motorcycles, and mopeds, as well as related accessories and spare parts under the Aprilia, Derbi, Gilera, Moto Guzzi, Piaggio, Scarabeo, and Vespa brand names. It has a 39.21 P/E ratio. The firm also provides three-and four-wheeler light transport sector vehicles, as well as related spare parts and accessories for commercial and private use under the Ape and Veicoli Commerciali brands.